{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:57:43Z","timestamp":1770047863928,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Health Commission capacity-building project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Inactivating vascular endothelial growth factor receptor (VEGFR) may improve the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in\n                    <jats:italic>EGFR<\/jats:italic>\n                    -mutant non-small cell lung cancer (NSCLC). The ATTENTION study (phase II, open-label, randomized, multicenter trial (Registration number: ChiCTR2100047453), evaluated the efficacy and safety of aumolertinib plus apatinib vs. aumolertinib alone in untreated,\n                    <jats:italic>EGFR<\/jats:italic>\n                    -mutant, advanced NSCLC. The primary endpoint was the 18-month PFS rate. Across 18 centers in China, 104 patients were enrolled to receive aumolertinib alone (n\u2009=\u200951) or with apatinib (n\u2009=\u200953). At a median follow-up duration of 19.4 months, aumolertinib plus apatinib outperformed aumolertinib alone in terms of the 18-month progression-free survival (PFS) rate (74% vs. 50%, P\u2009=\u20090.036), median PFS (not reached [NR] vs. 20.1 months, hazard ratio [HR]\u2009=\u20090.41, P\u2009=\u20090.017), and objective response rate (79% vs. 59%, P\u2009=\u20090.024). No grade 4\/5 treatment-related adverse effects (TRAEs) were observed, whereas grade 3 TRAEs occurred in 38% vs. 27% of patients, with hypertension (11%) and platelet count decrease (9%) being most common in the combination arm. Exploratory analysis revealed that PFS benefits from aumolertinib plus apatinib predominantly in those with\n                    <jats:italic>TP53<\/jats:italic>\n                    mutations. As an infusion-free option, aumolertinib plus apatinib demonstrated PFS benefits with manageable safety in patients with untreated,\n                    <jats:italic>EGFR<\/jats:italic>\n                    -mutant, advanced NSCLC.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02550-y","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:11:23Z","timestamp":1770009083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Fan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhendong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2419-9707","authenticated-orcid":false,"given":"Xiaolong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhefeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juyi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-7767","authenticated-orcid":false,"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shundong","family":"Cang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaiwen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3120-3017","authenticated-orcid":false,"given":"Qiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingfang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5063-5712","authenticated-orcid":false,"given":"Shangli","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"2550_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"2550_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s11427-023-2423-1","volume":"67","author":"S He","year":"2024","unstructured":"He, S. et al. Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors. Sci. China Life Sci. 67, 122\u2013131 (2024).","journal-title":"Sci. China Life Sci."},{"key":"2550_CR3","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","volume":"18","author":"G Gatta","year":"2017","unstructured":"Gatta, G. et al. Burden and centralized treatment in Europe of rare tumors: results of RARECAREnet\u2014a population-based study. Lancet Oncol. 18, 1022\u20131039 (2017).","journal-title":"Lancet Oncol."},{"key":"2550_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.9","volume":"1","author":"C Gridelli","year":"2015","unstructured":"Gridelli, C. et al. Non-small cell lung cancer. Nat. Rev. Dis. Prim. 1, 15009 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2550_CR5","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha, A., Dearden, S. & McCormack, R. EGFR mutation incidence in non-small cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am. J. Cancer Res. 5, 2892\u20132911 (2015).","journal-title":"Am. J. Cancer Res."},{"key":"2550_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks, L. E. et al. Oncogene-addicted metastatic non-small cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 339\u2013357 (2023).","journal-title":"Ann. Oncol."},{"key":"2550_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely, G. J. et al. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 22, 249\u2013274 (2024).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"2550_CR8","unstructured":"Medical Oncology Branch of China International, E. Promotive Association for, M., Health, C. & Chinese Association for Clinical, O. [China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage \u2163 non-small cell lung cancer (version 2023)]. Zhonghua. Yi Xue. Za Zhi. 103, 3160\u20133173 (2023)."},{"key":"2550_CR9","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard, D. et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N. Engl. J. Med. 389, 1935\u20131948 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2550_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","volume":"35","author":"E Felip","year":"2024","unstructured":"Felip, E. et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann. Oncol. 35, 805\u2013816 (2024).","journal-title":"Ann. Oncol."},{"key":"2550_CR11","doi-asserted-by":"crossref","unstructured":"Le, X. et al. A Multicenter open-label randomized phase ii study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-na\u00efve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial). J. Clin. Oncol. 43, 403\u2013411 (2024).","DOI":"10.1200\/JCO.24.00533"},{"key":"2550_CR12","unstructured":"Cho, B. C. et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N. Engl. J. Med. 391, 1486\u20131498 (2024)."},{"key":"2550_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito, H. et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced nonsquamous non-small cell lung cancer (NEJ026): interim analysis of an open-label, randomized, multicenter, phase 3 trial. Lancet Oncol. 20, 625\u2013635 (2019).","journal-title":"Lancet Oncol."},{"key":"2550_CR14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","volume":"39","author":"Q Zhou","year":"2021","unstructured":"Zhou, Q. et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study. Cancer Cell 39, 1279\u20131291 e1273 (2021).","journal-title":"Cancer Cell"},{"key":"2550_CR15","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa, K. et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer (RELAY): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 1655\u20131669 (2019).","journal-title":"Lancet Oncol."},{"key":"2550_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lungcan.2020.11.020","volume":"151","author":"N Yamamoto","year":"2021","unstructured":"Yamamoto, N. et al. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive nonsquamous non-small cell lung cancer: Survival follow-up results of the randomized JO25567 study. Lung Cancer 151, 20\u201324 (2021).","journal-title":"Lung Cancer"},{"key":"2550_CR17","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","volume":"15","author":"T Seto","year":"2014","unstructured":"Seto, T. et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase 2 study. Lancet Oncol. 15, 1236\u20131244 (2014).","journal-title":"Lancet Oncol."},{"key":"2550_CR18","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jtho.2021.05.006","volume":"16","author":"H Zhao","year":"2021","unstructured":"Zhao, H. et al. Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706). J. Thorac. Oncol. 16, 1533\u20131546 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"2550_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S2213-2600(21)00166-1","volume":"10","author":"Y Kawashima","year":"2022","unstructured":"Kawashima, Y. et al. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small cell lung cancer (NEJ026): overall survival analysis of an open-label, randomized, multicenter, phase 3 trial. Lancet Respir. Med. 10, 72\u201382 (2022).","journal-title":"Lancet Respir. Med."},{"key":"2550_CR20","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jamaoncol.2019.1847","volume":"5","author":"TE Stinchcombe","year":"2019","unstructured":"Stinchcombe, T. E. et al. Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1448\u20131455 (2019).","journal-title":"JAMA Oncol."},{"key":"2550_CR21","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jtho.2022.05.008","volume":"17","author":"MC Piccirillo","year":"2022","unstructured":"Piccirillo, M. C. et al. Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous NSCLC: the BEVERLY multicenter randomized phase 3 trial. J. Thorac. Oncol. 17, 1086\u20131097 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"2550_CR22","doi-asserted-by":"crossref","unstructured":"Lu, S. et al. Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS). Cancer Commun. 44, 1005\u20131017 (2024).","DOI":"10.1002\/cac2.12594"},{"key":"2550_CR23","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small cell lung cancer with EGFR Exon 19 deletion or L858R mutations. J. Clin. Oncol. 40, 3162\u20133171 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2550_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jtho.2021.10.024","volume":"17","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial. J. Thorac. Oncol. 17, 411\u2013422 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"2550_CR25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jtho.2020.11.028","volume":"16","author":"M Nagasaka","year":"2021","unstructured":"Nagasaka, M. et al. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J. Thorac. Oncol. 16, 740\u2013763 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"2550_CR26","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1016\/j.apsb.2023.03.007","volume":"13","author":"C Shi","year":"2023","unstructured":"Shi, C. et al. Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small cell lung cancer harboring uncommon EGFR mutations. Acta Pharm. Sin. B. 13, 2613\u20132627 (2023).","journal-title":"Acta Pharm. Sin. B."},{"key":"2550_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e10407","volume":"8","author":"L Li","year":"2022","unstructured":"Li, L. Two non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) G719X and L861Q mutations benefited from aumolertinib: two cases report and review of the literature. Heliyon 8, e10407 (2022).","journal-title":"Heliyon"},{"key":"2550_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.19.00931","volume":"38","author":"JH Cho","year":"2020","unstructured":"Cho, J. H. et al. Osimertinib for patients with non-small cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J. Clin. Oncol. 38, 488\u2013495 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2550_CR29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","volume":"17","author":"H Kenmotsu","year":"2022","unstructured":"Kenmotsu, H. et al. Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study. J. Thorac. Oncol. 17, 1098\u20131108 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"2550_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small cell lung cancer. N. Engl. J. Med. 378, 113\u2013125 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2550_CR31","doi-asserted-by":"publisher","first-page":"175883592412276","DOI":"10.1177\/17588359241227677","volume":"16","author":"G Zhou","year":"2024","unstructured":"Zhou, G., Guo, L., Xu, J., Tang, K. & Chen, J. Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis. Ther. Adv. Med. Oncol. 16, 17588359241227677 (2024).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2550_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1101\/gad.14.1.34","volume":"14","author":"R Ravi","year":"2000","unstructured":"Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14, 34\u201344 (2000).","journal-title":"Genes Dev."},{"key":"2550_CR33","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1158\/0008-5472.CAN-14-2305","volume":"75","author":"M Schwaederle","year":"2015","unstructured":"Schwaederle, M. et al. VEGF-a expression correlates with TP53 mutations in non-small cell lung cancer: implications for antiangiogenesis therapy. Cancer Res. 75, 1187\u20131190 (2015).","journal-title":"Cancer Res."},{"key":"2550_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101580","volume":"8","author":"EB Garon","year":"2023","unstructured":"Garon, E. B. et al. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results. ESMO Open 8, 101580 (2023).","journal-title":"ESMO Open"},{"key":"2550_CR35","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13046-021-02069-4","volume":"40","author":"C Xie","year":"2021","unstructured":"Xie, C. et al. Apatinib triggers autophagic and apoptotic cell death via VEGFR2\/STAT3\/PD-L1 and ROS\/Nrf2\/p62 signaling in lung cancer. J. Exp. Clin. Cancer Res. 40, 266 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2550_CR36","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","volume":"7","author":"S Zhao","year":"2019","unstructured":"Zhao, S. et al. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer. Cancer Immunol. Res. 7, 630\u2013643 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2550_CR37","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","volume":"102","author":"S Tian","year":"2011","unstructured":"Tian, S. et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 102, 1374\u20131380 (2011).","journal-title":"Cancer Sci."},{"key":"2550_CR38","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.chest.2020.03.010","volume":"158","author":"X Wang","year":"2020","unstructured":"Wang, X. & Ji, X. Sample size estimation in clinical research: from randomized controlled trials to observational studies. Chest 158, S12\u2013S20 (2020).","journal-title":"Chest"},{"key":"2550_CR39","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1002\/sim.2864","volume":"26","author":"JP Klein","year":"2007","unstructured":"Klein, J. P., Logan, B., Harhoff, M. & Andersen, P. K. Analyzing survival curves at a fixed point in time. Stat. Med. 26, 4505\u20134519 (2007).","journal-title":"Stat. Med."},{"key":"2550_CR40","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","volume":"33","author":"KV Ballman","year":"2015","unstructured":"Ballman, K. V. Biomarker: predictive or prognostic? J. Clin. Oncol. 33, 3968\u20133971 (2015).","journal-title":"J. Clin. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02550-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02550-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02550-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:11:25Z","timestamp":1770009085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02550-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2550"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02550-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yu Xu, Lei Zhang, and Shangli Cai are employees of Burning Rock Biotech. No other conflicts were reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}